The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease.

Autor:	Asano S; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa-ken, Japan., Fukushima N; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa-ken, Japan. Electronic address: naofuku0401@gmail.com., Yamada K; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka-shi, Kanagawa-ken, Japan.
Jazyk:	angličtina
Zdroj:	Pediatrics and neonatology [Pediatr Neonatol] 2024 Sep; Vol. 65 (5), pp. 441-444. Date of Electronic Publication: 2024 Jan 23.
DOI:	10.1016/j.pedneo.2023.09.012
Abstrakt:	Background: Approximately 10-20 % of individuals develop a recrudescent or persistent fever after intravenous immunoglobulin (IVIG) infusion for the initial treatment of Kawasaki disease. The aim of this study was to evaluate the efficacy and safety of the initial IVIG treatment of Kawasaki disease based on duration of infusion. Methods: This retrospective, single-center study included 53 patients with Kawasaki disease who were initially treated with 2 g/kg of IVIG by means of a single infusion from June 2018 to August 2019. We classified patients into two groups based on the duration of the infusion: the 12-h group and the 24-h group. We compared the treatment response of the primary IVIG and its adverse events using the Mann-Whitney U test and Fisher's exact or Chi-square tests. Results: There were no significant differences in the response to initial IVIG treatment between the two groups. The duration from treatment onset to defervescence was shorter in the 12-h group than the 24-h group (7 h vs. 12 h, respectively, p = 0.07); however, this was not significant. There were no significant between-group differences regarding adverse events. Conclusion: We concluded that the initial 12-h IVIG treatment was comparable to the 24-h treatment in terms of efficacy and safety. This will enable physicians to feel confident about pursuing a shorter course of treatment with similar results as conventional treatment and decide on administering additional therapy to their patients. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. None (Copyright © 2024 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu